Acarbose capsule, a diabetes drug with a market value of nearly 10 billion, passed the consistency evaluation

LVYE Pharmaceutical Group announced that its core product "acarbose capsule" (trade name: Beixi) for the treatment of diabetes has been approved by the State Drug Administration and passed the quality and efficacy consistency evaluation of generic drugs Through the consistency evaluation, it is proved that the quality and efficacy of Besch and the original research drug are consistent, which can realize clinical mutual substitution and effectively guarantee the drug demand of more patients China is the largest country of diabetes, with a population of about 114 million Epidemiological investigation shows that more than 80% of the patients with diabetes in China have postprandial hyperglycemia In the newly diagnosed diabetic patients, the patients with simple postprandial blood glucose increase accounted for nearly 50% Among all hypoglycemic drugs, acarbose has a prominent advantage in controlling postprandial blood glucose, which is suitable for Chinese diet habits and has become one of the most widely used oral hypoglycemic drugs with the most evidence of clinical benefits In 2018, the market value of acarbose products in China is estimated to be about 10 billion yuan As one of the large varieties of diabetes drugs, acarbose has two dosage forms: tablet and capsule At present, Bechi is the only acarbose capsule dosage form in the Chinese market and the third most commonly used acarbose product From the perspective of clinical efficacy, besia carbo sugar capsule does not need to be chewed For elderly patients and patients with bad teeth, it is more convenient to take and effectively improve the compliance of patients At present, Beixi has been included in the national basic drug catalog, and as a class a Medicare drug, it has been included in the national basic medical insurance and industrial injury insurance drug catalog, in order to effectively guarantee the drug demand of patients and reduce the drug burden Through the consistency evaluation, it is expected to further accelerate the substitution of the drug for the original varieties.